Publication Name	World Journal of Hepatology
Manuscript ID	17589
Country	Canada

Received	2015-03-14 14:23
Peer-Review Started	2015-03-16 09:08
To Make the First Decision	2015-04-27 15:30
Return for Revision	2015-04-30 15:44
Revised	2015-05-05 03:36
Second Decision	2015-05-29 15:29
Accepted by Journal Editor-in-Chief	2015-06-01 11:51
Accepted by Company Editor-in-Chief	2015-06-08 16:06
Articles in Press	2015-06-08 16:31
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2015-06-09 17:46
Publish the Manuscript Online	2015-06-29 17:40

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Systematic review: Preventive and therapeutic applications of metformin in liver disease
Manuscript Source	Invited Manuscript
All Author List	Aparna Bhat, Giada Sebastiani and Mamatha Bhat
Funding Agency and Grant Number
Corresponding Author	Mamatha Bhat, MD, Division of Gastroenterology and Hepatology, McGill University Health Centre, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada. mamatha.bhat@mail.mcgill.ca
Key Words	Non-alcoholic fatty liver disease; Metformin; Chemoprevention; Hepatocellular carcinoma; Hepatitis C
Core Tip	There has recently been a growing literature on the use of metformin as a potential preventive and therapeutic agent for various chronic liver diseases and hepatic malignancies. We therefore decided to review the efficacy of metformin across the spectrum of liver disease and malignancies. Based on our systematic review, there is insufficient evidence to recommend use of metformin in the adjunctive treatment of non-alcoholic fatty liver disease and hepatitis C. However, there is good evidence for a chemopreventive role against hepatocellular carcinoma among patients with diabetes and chronic liver disease, and metformin should be continued in patients even with cirrhosis to provide this benefit.
Publish Date	2015-06-29 17:40
Citation	Bhat A, Sebastiani G, Bhat M. Systematic review: Preventive and therapeutic applications of metformin in liver disease. World J Hepatol 2015; 7(12): 1652-1659
URL	http://www.wjgnet.com/1948-5182/full/v7/i12/1652.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i12.1652

Full Article (PDF)	WJH-7-1652.pdf
Full Article (Word)	WJH-7-1652.doc
Manuscript File	17589-Review.docx
Answering Reviewers	17589-Answering reviewers.pdf
Audio Core Tip	17589-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	17589-Conflict-of-interest statement.pdf
Copyright License Agreement	17589-Copyright assignment.pdf
Peer-review Report	17589-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	17589-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	17589-Scientific misconduct check.pdf
Scientific Editor Work List	17589-Scientific editor work list.pdf